SCHEMBL3430600

SCHEMBL3430600

CCNCC(C)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.61
AOC3 Q16853 2/20 0.61
BCHE P06276 2/20 0.49
HTT P42858 1/20 0.46
LMNA P02545 1/20 0.44
HIF1A Q16665 1/20 0.44
GALR3 O60755 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TRPA1 O75762 3/20 0.44
RIPK1 Q13546 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8278973 1.00 TAAR1 (0.61) TAAR1AOC3BCHEHTTLMNA
SCHEMBL11046082 0.89 TAAR1 (0.68) TAAR1AOC3BCHEMEN1KMT2A
SCHEMBL23081526 0.83 TAAR1 (0.57) TAAR1AOC3BCHEMEN1KMT2A
SCHEMBL13911257 0.83 TAAR1 (0.57) TAAR1AOC3BCHEMEN1KMT2A
SCHEMBL17308024 0.83 TAAR1 (0.61) TAAR1AOC3BCHEMEN1KMT2A
SCHEMBL12231496 0.82 GRIN1 (0.57) TAAR1AOC3HTTLMNAHIF1A
SCHEMBL11179553 0.81 TAAR1 (0.59) TAAR1AOC3BCHEHTTMEN1
Hydrochloric Acid SCHEMBL15573475 0.81 TAAR1 (0.64) TAAR1AOC3BCHEHTTMEN1
SCHEMBL19381906 0.81 TAAR1 (0.59) TAAR1AOC3BCHEHTTMEN1
SCHEMBL7791795 0.80 TAAR1 (0.53) TAAR1AOC3BCHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1343024-A Organic amine used as additive in electrochemical battery MERCK PATENT GMBH (DE) 2002-04-03 CN claimed
EP-1187244-A2 Organic amines as additives for electrochemical cells MERCK PATENT GmbH (DE) 2002-03-13 EP claimed
US-20230174487-A1 PHENYLPROPIONAMIDE COMPOUND AND USE THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-06-08 US disclosed
US-20230174487-A1 PHENYLPROPIONAMIDE COMPOUND AND USE THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-06-08 US disclosed
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X FORMA THERAPEUTICS, INC. 2023-03-02 US disclosed
US-10253035-B2 Eis inhibitors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2019-04-09 US disclosed
US-10208000-B2 Eis inhibitors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2019-02-19 US disclosed
US-20180162867-A1 EIS INHIBITORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2018-06-14 US disclosed
US-20100323098-A1 ELECTRODE MATERIAL FOR RECHARGEABLE LITHIUM BATTERY, ELECTRODE STRUCTURAL BODY COMPRISING SAID ELECTRODE MATERIAL, RECHARGEABLE LITHIUM BATTERY HAVING SAID ELECTRODE STRUCTURAL BODY, PROCESS FOR THE PRODUCTION OF SAID ELECTRODE STRUCTURAL BODY, AND PROCESS FOR THE PRODUCTION OF SAID RECHARGEABLE LITHIUM BATTERY CANON KABUSHIKI KAISHA (JP) 2010-12-23 US disclosed
US-7803290-B2 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2010-09-28 US disclosed
US-20080090152-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structual body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2008-04-17 US disclosed
US-7141187-B2 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2006-11-28 US disclosed
US-20060237697-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2006-10-26 US disclosed
US-20030157407-A1 Electrode material for rechargeable lithium battery, electrode structural body comprising said electrode material, rechargeable lithium battery having said electrode structural body, process for the production of said electrode structural body, and process for the production of said rechargeable lithium battery CANON KABUSHIKI KAISHA (JP) 2003-08-21 US disclosed
EP-1313158-A2 Electrode material for rechargeable lithium battery, electrode comprising said electrode material, rechargeable lithium battery having said electrode , and process for the production thereof CANON KABUSHIKI KAISHA (JP) 2003-05-21 EP disclosed
CN-1343024-A Organic amine used as additive in electrochemical battery MERCK PATENT GMBH (DE) 2002-04-03 CN disclosed
EP-1187244-A2 Organic amines as additives for electrochemical cells MERCK PATENT GmbH (DE) 2002-03-13 EP disclosed
EP-0094191-B1 ANTIULCER 2-GUANIDINO-4-(2-SUBSTITUTED-AMINO-4-IMIDAZOLYL)-THIAZOLES AND PROCESS THEREFOR PFIZER INC. (US) 1988-04-20 EP disclosed
US-4435396-A FROM 2-AMINO-5-ACETYLOXAZOLE PFIZER INC. (US) 1984-03-06 US disclosed
EP-0094191-A1 Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)-thiazoles and process therefor PFIZER INC. (US) 1983-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065368-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X USP9X, USP19, USP39 TAAR1 4461/4885AOC3 3109/4885BCHE 1178/4885
US-20180162867-A1 EIS INHIBITORS EP300, ACAT1, ACAT2 TAAR1 3281/4885AOC3 2660/4885BCHE 1348/4885
US-10253035-B2 Eis inhibitors EP300, ACAT1, ACAT2 TAAR1 3281/4885AOC3 2660/4885BCHE 1348/4885
US-20230174487-A1 PHENYLPROPIONAMIDE COMPOUND AND USE THEREOF PAH, TRPV1, TRPA1 TAAR1 1316/4885AOC3 2234/4885BCHE 1102/4885
US-10208000-B2 Eis inhibitors ABCC1, ATP5ME, ABCG2 TAAR1 3227/4885AOC3 3472/4885BCHE 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.